According to FutureWise analysis the market for Corneal Endothelial Cell Transplant in 2023 was US$ 303.2 million, and is expected to reach US$ 630 million by 2031 at a CAGR of 9.30%.
A corneal transplant is a technique for replacing a damaged or diseased cornea that may have developed as a result of an eye accident or an eye condition. The two most common transplant procedures worldwide are penetrating keratoplasty (full thickness cornea transplant) and endothelial keratoplasty (back layer cornea transplant). Vision blurring due to a sick cornea indicates the need for a corneal transplant.
The monolayer of cells forming the human corneal endothelium is critical to the maintenance of corneal transparency and is not known to regenerate in vivo. Hence, the roughly 150,000 corneal transplants that are performed each year are most frequently attributed to the malfunctioning of these cells. Even though current corneal transplantation has a success rate of over 90% after a year, the longer-term results are less encouraging, with a success rate of only about 70% after five years. Nonimmunologic graft failure and allograft endothelial rejection are the main problems. Moreover, fewer corneal transplants can be performed because of the severe global corneal donor shortage. Human corneal endothelial cells (HCECs) can now be grown in vitro thanks to advances in our understanding of corneal endothelial cell biology, opening up new possibilities for the creation of novel tissue-engineered human corneal endothelium.
Request a Free Sample @ https://www.futurewiseresearch.com/healthcare-market-research/Corneal-Endothelial-Cell/15193
Corneal Endothelial Cell Transplant Market Segmentation:
By Techniques
- Descemet Stripping Endothelial Keratoplasty (DSEK)
- Deep Lamellar Endothelial Keratoplasty (DLEK)
- Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)
- Descemet Membrane Endothelial Keratoplasty (DMEK)
- Pre-Descemet Endothelial Keratoplasty (PDEK)
- Descemetorhexis without Endothelial Keratoplasty (DWEK)
- Descemet Stripping Only (DSO)
- Descemet Membrane Endothelial Transfer (DMET)
By Indications
- Fuchs dystrophy
- Fungal Corneal Ulcer
- Keratoconus
- Keratitis
- Acquired Pseudophakic
- Bullous keratopathy
- Iridocorneal endothelial syndrome
- Corneal Stromal Dystrophies
- Postinfective Keratitis
- Other Indications
By End-User
- Hospitals
- Eye Clinic
- Ambulatory Surgical Centers
By Region
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Competitive Landscape in the Corneal Endothelial Cell Transplant Market:
- Ajl Ophthalmic SA
- Exactech, Inc.
- Keramed Inc.
- Lifeline Scientific
- CorneaGen
- Corneat Vision
- CryoLife Inc.
- Kohler GmbH
- Lifecell Corporation
- Medtronic plc.
- Organogenesis Inc.
- Presbia plc.
Buy now the latest version of this report:
https://www.futurewiseresearch.com/contact.aspx?rpt=15193%20&type=discount
**Objectives of this Study: **
- To provide a comprehensive analysis of the Corneal Endothelial Cell Transplant Market By Techniques, By Indications, By End-User and By Region.
- To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
- To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
- To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
Flexible Delivery Model:
- We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
- The customization services offered are free of charge with the purchase of any license of the report.
- You can directly share your requirements/changes to the current table of contents to: sales@futurewiseresearch.com
FutureWise Research
Contact Person: Vinay Thaploo.
Email: sales@futurewiseresearch.com
Contact Number: Asia: +91 8605575209 | USA: +1 3477094931
Website: www.futurewiseresearch.com
